New Clinical Data Released at the World Congress of Neuroendoscopy Conclusively Points to Vycor's VBAS Reducing Post Operative Patient Length of Stay in Hospital

Clinical Data Supports Management's Belief that VBAS Saves Hospital Money

Nov 18, 2015, 08:02 ET from Vycor Medical, Inc.

BOCA RATON, Florida, November 18, 2015 /PRNewswire/ --

Vycor Medical, Inc. (OTCQB: VYCO) reports that a "Poster" presented at the VII World Congress of Neuroendoscopy recently held in Puerto Vallarta on a 64 Patient retrospective study showed statistically meaningful reductions in patient post operative hospital stay, while still providing effective access.

The paper looked at Intracerebral Hemorrhage Evacuation that accounts for 10-15% of cerebrovascular disease and compared three different treatment approaches: medical management and observation; drainage through a VBAS with endoscopic assistance; and finally drainage through a conventional craniotomy. The analysis was performed by neurosurgeons at the Department of Neurological Surgery, National Institute of Neurology and Neurosurgery "Manuel Velasco Suarez" Mexico City, Mexico and was presented earlier this month.

The study states that there is no agreement on the selection of type of treatment for Intracerebral Hemorrhage. In the retrospective analysis, 64 patients who had undergone one of the three approaches were analyzed.  Complete drainage of the of the hematoma was achieved in 83.3% of the cases using the VBAS but even more significant was the average hospital stay of 8.08 days with a statistically significant difference against the other two groups. Furthermore, mortality at 6 months had a significant difference between the medical treatment group and the VBAS and Endoscope group, 42.9% vs 0% for the VBAS and Endoscope group.

"We have for some time had direct feedback from physicians that they believed using VBAS reduced the Operating Room time in any given procedure which is a large component of overall cost', said Peter Zachariou, CEO of Vycor. "The other main cost born by the hospital is the time the patient has to stay in its care. This clinical data further supports our belief that not only does VBAS improve patient outcome it furthermore saves hospitals money. This high-quality clinical data can help support the greater usage of VBAS and its adoption as the standard of care for brain retraction and access."

The article follows on from six other published studies this year, including one featured on the cover of the Journal of Neurosurgery. It is also the fifth clinical paper or abstract for VBAS published internationally highlighting its growing adoption.

About ViewSite™ Surgical Access System 

Vycor Medical's ViewSite™ Surgical Access Systems (VBAS) is a suite of clear cylindrical minimally invasive disposable devices that hold the potential for speedier, safer and more economical brain surgeries and a quicker patient discharge. VBAS is designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery and add tangible value to the professional medical community.

The company is ISO 13485:2003 compliant, has U.S. FDA 510(k) clearance for brain and spine surgeries and full regulatory approvals for brain in Australia, Brazil, Canada, China, Europe (EU - Class III), Korea and Japan and is seeking or has partial regulatory approvals in India, Russia, Taiwan and Vietnam. For an overview of Vycor Medical's VBAS, see VBAS Video.

About Vycor Medical 

Vycor Medical (OTCQB: VYCO) is dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions. The company has a portfolio of FDA cleared medical solutions that are changing and improving lives every day. The company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach.

For the latest information on the company, including media and other coverage, and to learn more, visit, or    

Investor Relations:
Ronald A. Both, Senior Managing Director
Tel +1-949-574-3860

SOURCE Vycor Medical, Inc.